The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
Open accessAbstract
Purpose: BRAF V600 mutations are frequently found in several glioma subtypes, including pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less commonly in glioblastoma. We sought to determine the activity of vemurafenib, a selective inhibitor of BRAF V600, in patients with gliomas that harbor this mutation. Patients and Methods: The VE-BASKET study was an open-label, nonrandomized, multicohort study for BRAF V600-mutant nonmelanoma cancers. Patients with BRAF V600-mutant glioma received vemurafenib 960 mg twice per day continuously until disease progression, withdrawal, or intolerable adverse effects. Key end points included confirmed objective response rate by RECIST version 1.1, progression-free survival, overall survival, and safety. Results: Twenty-four patients (median age, 32 years; 18 female and six male patients) with glioma, including malignant diffuse glioma (n = 11; six glioblastoma and five anaplastic astrocytoma), PXA (n = 7), anaplastic ganglioglioma (n = 3), pilocytic astrocytoma (n = 2), and high-grade glioma, not otherwise specified (n = 1), were treated. Confirmed objective response rate was 25% (95% CI, 10% to 47%) and median progression-free survival was 5.5 months (95% CI, 3.7 to 9.6 months). In malignant diffuse glioma, best response included one partial response and five patients with stable disease, two of whom had disease stabilization that lasted more than 1 year. In PXA, best response included one complete response, two partial responses, and three patients with stable disease. Additional partial responses were observed in patients with pilocytic astrocytoma and anaplastic ganglioglioma (one each). The safety profile of vemurafenib was generally consistent with that of previously published studies. Conclusion: Vemurafenib demonstrated evidence of durable antitumor activity in some patients with BRAF V600-mutant gliomas, although efficacy seemed to vary qualitatively by histologic subtype. Additional study is needed to determine the optimal use of vemurafenib in patients with primary brain tumors and to identify the mechanisms driving differential responses across histologic subsets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 2×
“(%) Male 1 (14) 3 (27) 2 (33) 6 (25) Female 6 (86) 8 (73) 4 (67) 18 (75) Median age, years (range) 29 (18-57) 42 (23-57) 25.”
Self-citationComprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · cited 5×
“(%) 0 5 (71) 5 (45) 2 (33) 12 (50) 1 1 (14) 4 (36) 1 (17) 6 (25) 2 0 2 (18) 2 (33) 4 (17) Missing 1 (14) 0 1 (17) 2 (8) Prior radiotherapy, No.”
InfluentialSelf-citationKreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Planchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, Å., Giannone, V., D'Amelio, A. M., Zhang, P., Mookerjee, B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30679-4 · Cited by 1,360
Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., Silvani, A., Fink, K. L., et al. (2015) · JAMA · doi:10.1001/jama.2015.16669 · Cited by 1,259
Schindler, G., Capper, D., Meyer, J., Janzarik, W., Omran, H., Herold-Mende, C., Schmieder, K., Wesseling, P., Mawrin, C., Hasselblatt, M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0802-6 · Cited by 1,034
Ascierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30122-x · Cited by 1,022
Lomustine and Bevacizumab in Progressive Glioblastoma
Wick, W., Gorlia, T., Bendszus, M., Taphoorn, M., Sahm, F., Harting, I., Brandes, A. A., Taal, W., Domont, J., Idbaih, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707358 · Cited by 970
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902
Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C., Cabanillas, M. E., Urbanowitz, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.6785 · Cited by 892
Self-citationPlanchard, D., Besse, B., Groen, H. J. M., Souquet, P.-J., Quoix, E., Baik, C. S., Barlesi, F., Kim, T. M., Mazieres, J., Novello, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30146-2 · Cited by 888
Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis
Lamborn, K. R., Chang, S. M., & Prados, M. D. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000620 · Cited by 546
Corcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2471 · Cited by 507
Implementing Genome-Driven Oncology
Hyman, D. M., Taylor, B. S., & Baselga, J. (2017) · Cell · doi:10.1016/j.cell.2016.12.015 · Cited by 503
Self-citationGlioblastoma targeted therapy: updated approaches from recent biological insights
Touat, M., Idbaih, A., Sanson, M., & Ligon, K. L. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx106 · Cited by 441
Self-citationDiamond, E. L., Subbiah, V., Lockhart, A. C., Blay, J.-Y., Puzanov, I., Chau, I., Raje, N. S., Wolf, J., Erinjeri, J. P., Torrisi, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5029 · Cited by 413
Self-citationIntratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma
Qazi, M. A., Vora, P., Venugopal, C., Sidhu, S. S., Moffat, J., Swanton, C., & Singh, S. K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx169 · Cited by 408
Brose, M. S., Cabanillas, M. E., Cohen, E. E. W., Wirth, L. J., Riehl, T., Yue, H., Sherman, S. I., & Sherman, E. J. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30166-8 · Cited by 388
Self-citationTherapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas
Lassaletta, A., Zapotocky, M., Mistry, M., Ramaswamy, V., Honnorat, M., Krishnatry, R., Guerreiro Stucklin, A., Zhukova, N., Arnoldo, A., Ryall, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.8726 · Cited by 349
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia
Tiacci, E., Park, J. H., De Carolis, L., Chung, S. S., Broccoli, A., Scott, S., Zaja, F., Devlin, S., Pulsoni, A., Chung, Y. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506583 · Cited by 348
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas
Dougherty, M. J., Santi, M., Brose, M. S., Ma, C., Resnick, A. C., Sievert, A. J., Storm, P. B., & Biegel, J. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq007 · Cited by 324
Dias-Santagata, D., Lam, Q., Vernovsky, K., Vena, N., Lennerz, J. K., Borger, D. R., Batchelor, T. T., Ligon, K. L., Iafrate, A. J., Ligon, A. H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017948 · Cited by 315
Mistry, M., Zhukova, N., Merico, D., Rakopoulos, P., Krishnatry, R., Shago, M., Stavropoulos, J., Alon, N., Pole, J. D., Ray, P. N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3922 · Cited by 288
Shah, G. D., Kesari, S., Xu, R., Batchelor, T. T., O'Neill, A. M., Hochberg, F. H., Levy, B., Bradshaw, J., & Wen, P. Y. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000529 · Cited by 195
Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells
Koelsche, C., Wöhrer, A., Jeibmann, A., Schittenhelm, J., Schindler, G., Preusser, M., Lasitschka, F., von Deimling, A., & Capper, D. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1100-2 · Cited by 191
Vemurafenib in pediatric patients with BRAFV 600E mutated high‐grade gliomas
Bautista, F. J., Paci, A., Minard‐Colin, V., Dufour, C., Grill, J., Lacroix, L., Varlet, P., Valteau‐Couanet, D., & Geoerger, B. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24891 · Cited by 148
Galanis, E., Buckner, J. C., Maurer, M. J., Sykora, R., Castillo, R., Ballman, K. V., & Erickson, B. J. (2006) · Neuro-Oncology · doi:10.1215/15228517-2005-005 · Cited by 139
Chamberlain, M. C. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1176-5 · Cited by 139
Adaptive Two‐Stage Designs for Single‐Arm Phase IIA Cancer Clinical Trials
Lin, Y., & Shih, W. J. (2004) · Biometrics · doi:10.1111/j.0006-341x.2004.00193.x · Cited by 94
Huillard, E., Hashizume, R., Phillips, J. J., Griveau, A., Ihrie, R. A., Aoki, Y., Nicolaides, T. P., Perry, A., Waldman, T. A., McMahon, M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117255109 · Cited by 87
Burger, M. C., Ronellenfitsch, M. W., Lorenz, N. I., Wagner, M., Voß, M., Capper, D., Tzaridis, T., Herrlinger, U., Steinbach, J. P., Stoffels, G., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.6013 · Cited by 70
Dabrafenib and trametinib in BRAFV600E mutated glioma
Brown, N. F., Carter, T. J., Kitchen, N. D., & Mulholland, P. J. (2017) · CNS Oncology · doi:10.2217/cns-2017-0006 · Cited by 67
Johanns, T. M., Ferguson, C., Grierson, P. M., Dahiya, S. M., & Ansstas, G. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.7032 · Cited by 62
BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma
Migliorini, D., Aguiar, D., Vargas, M. I., Lobrinus, A. J., & Dietrich, P. (2017) · Neurology · doi:10.1212/wnl.0000000000003767 · Cited by 40
Cited by
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048
Management of glioblastoma: State of the art and future directions
Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21613 · Cited by 1,972
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review
Schaff, L. R., & Mellinghoff, I. K. (2023) · JAMA · doi:10.1001/jama.2023.0023 · Cited by 1,271
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Glioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 704
Metadata
- Authors
- Kaley, T., Touat, M., Subbiah, V., Hollebecque, A., Rodon, J., Lockhart, A. C., Keedy, V., Bielle, F., Hofheinz, R.-D., Joly, F., Blay, J.-Y., Chau, I., Puzanov, I., Raje, N. S., Wolf, J., DeAngelis, L. M., Makrutzki, M., Riehl, T., Pitcher, B., Baselga, J., & Hyman, D. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-12-10
- Volume
- 36
- Issue
- 35
- Pages
- 3477-3484
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2896001331
- Cited by
- 350
- References
- 43
- FWCI
- 16.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.